CANCER MONITORING METHOD, CALCULATION METHOD, EVALUATION DEVICE, CALCULATION DEVICE, EVALUATION PROGRAM, CALCULATION PROGRAM, AND EVALUATION SYSTEM

The method uses specific amino acid concentrations to predict cancer recurrence through formulas, offering accurate and reliable information for treatment planning and reducing post-surgery surveillance burden.

JP7595611B2Active Publication Date: 2024-12-06AJINOMOTO CO INC
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
JP2022071128
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-12-01
Filing Date
2022-04-22
Publication Date
2024-12-06
Estimated Expiration
2037-11-30

AI Technical Summary

Technical Problem

Current methods lack reliable biomarkers for predicting or evaluating the possibility of cancer recurrence after surgical therapy, relying on short-term post-surgery changes in blood amino acid concentrations and varying evaluation targets.

Method used

An evaluation method utilizing the concentration values of specific amino acids (12 or 21 types) to assess the likelihood of cancer recurrence, employing formulas and statistical analysis for accurate prediction.

Benefits of technology

Provides highly reliable information on the possibility of cancer recurrence, aiding in treatment planning and reducing the burden of post-surgery surveillance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595611000001
    Figure 0007595611000001
  • Figure 0007595611000002
    Figure 0007595611000002
  • Figure 0007595611000003
    Figure 0007595611000003
Patent Text Reader

Abstract

The present invention addresses the problem of providing an evaluation method that can provide highly reliable information that can be used as a reference for determining the possibility of cancer recurrence. [Solution] In this embodiment, the possibility of cancer recurrence in a subject is evaluated using concentration values ​​of at least one of Glu, Ser, α-ABA, Val, Met, Lys, Ile, Leu, Trp, His, Orn, and Pro, or at least two of Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Trp, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, α-ABA, and Gly in the blood of the subject in whom cancer has been found.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a cancer monitoring method, a calculation method, an evaluation device, an evaluation program, an evaluation system, and a terminal device. [Background technology]

[0002] Surgical therapy is a treatment to remove cancer lesions, and is said to be the first choice for treating solid cancers, excluding leukemia, etc. Cancer can be cured if it can be completely removed, so surgical therapy is the most direct method of treatment.

[0003] For example, in cases of early stage stomach cancer without metastasis, surgical therapy can cure the cancer almost 100%. However, surgery is not only performed on early stage cancer, but also on cancer that has progressed to a certain extent. In normal cancer surgery, not only the original cancer site (primary site) is removed, but also the surrounding lymph nodes in anticipation of metastasis. If there is metastasis to the lymph nodes, if the lymph nodes are left behind, the cancer will recur regardless of whether they are visible or not, so the lymph nodes are removed slightly wider than the area where there is a risk of metastasis. In this way, surgical therapy can completely cure cancer if the cancer remains at the primary site, or if there is metastasis, it remains in a relatively small number of lymph nodes. However, in reality, minute cancer cells may remain after surgery, causing recurrence after surgery.

[0004] Postoperative follow-up (or surveillance) is performed with the aim of improving prognosis by early detection and treatment of recurrence. Postoperative follow-up is performed by combining interviews and examinations, blood tests such as tumor marker tests, and imaging tests. These tests must be continuously performed after surgery to check for the presence or absence of cancer recurrence, which is a burden for patients. If it is possible to distinguish, predict, or evaluate the risk of recurrence due to surgical treatment before and for a certain period after surgery, there is an advantage in that the burden of tests can be reduced. In addition, the results of the above-mentioned distinction, prediction, or evaluation can also be used as a basis for patients to decide on a treatment method. Furthermore, the results of the above-mentioned distinction, prediction, or evaluation can be expected to be of great use in formulating treatment plans for patients, improving treatment outcomes for cancer, and preventing recurrence due to metastatic cancer and managing the prognosis.

[0005] On the other hand, it is known that blood amino acid concentrations change due to surgical treatment for cancer. For example, it has been reported that blood serine and glutamic acid concentrations normalize in breast cancer patients after surgery (Non-Patent Document 1). It has also been reported that blood glutamine, tryptophan, alanine, glycine, and arginine concentrations decrease in esophageal and lung cancer patients immediately after chest surgery (Non-Patent Document 2). Furthermore, it has been reported that alanine and aspartic acid increase after surgery in gastric and breast cancer patients (Non-Patent Document 3).

[0006] In addition, as prior patents, Patent Documents 1, 2, and 3 have been published on a method for relating amino acid concentration to a biological state. In addition, Patent Document 4 on a method for evaluating the state of lung cancer using amino acid concentration, Patent Document 5 on a method for evaluating the state of breast cancer using amino acid concentration, Patent Document 6 on a method for evaluating the state of colorectal cancer using amino acid concentration, Patent Document 7 on a method for evaluating the state of cancer using amino acid concentration, Patent Document 8 on a method for evaluating the state of gastric cancer using amino acid concentration, Patent Document 9 on a method for evaluating cancer type using amino acid concentration, Patent Document 10 on a method for evaluating the state of female reproductive cancer using amino acid concentration, Patent Document 11 on a method for evaluating the state of prostate disease including prostate cancer using amino acid concentration, Patent Document 12 on a method for evaluating the state of pancreatic cancer using amino acid concentration, Patent Document 13 on a method for evaluating the state of pancreatic cancer risk disease using amino acid concentration, and Patent Document 14 on a method for evaluating the therapeutic effect of cancer immunotherapy using amino acid concentration have been published. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] International Publication No. 2004 / 052191 [Patent Document 2] International Publication No. 2006 / 098192 [Patent Document 3] International Publication No. 2009 / 054351 [Patent Document 4] International Publication No. 2008 / 016111 [Patent Document 5] International Publication No. 2008 / 075662 [Patent Document 6] International Publication No. 2008 / 075663 [Patent Document 7] International Publication No. 2008 / 075664 [Patent Document 8] International Publication No. 2009 / 099005 [Patent Document 9] International Publication No. 2009 / 110517 [Patent Document 10] International Publication No. 2009 / 154296 [Patent Document 11] International Publication No. 2009 / 154297 [Patent Document 12] International Publication No. 2014 / 084290 [Patent Document 13] JP 2014-106114 A [Patent Document 14] International Publication No. 2013 / 168550 [Non-patent literature]

[0008] [Non-Patent Document 1] Cancer Invest. 2004;22(2):203-10. [Non-Patent Document 2] Cancer. 1988;62(2):355-60. [Non-Patent Document 3] J Transl Med. 2015;13:35 Summary of the Invention [Problem to be solved by the invention]

[0009] However, Non-Patent Documents 1, 2, and 3 all report on short-term results after surgery, and there are no reports on changes in blood amino acid concentrations related to recurrence after cancer surgical therapy. In addition, when using the index groups disclosed in Patent Documents 1-14 to evaluate the possibility of cancer recurrence, the evaluation targets are different.

[0010] In other words, there are no biomarkers using amino acids in blood that predict, distinguish, or evaluate the possibility of cancer recurrence.

[0011] The present invention has been made in consideration of the above problems, and aims to provide an evaluation method, evaluation device, evaluation program, evaluation system, and terminal device that utilize blood amino acid concentrations to provide highly reliable information that can be useful in determining the possibility of cancer recurrence. [Means for solving the problem]

[0012] As a result of intensive research aimed at solving the above-mentioned problems, the present inventors discovered that the possibility of cancer recurrence can be accurately evaluated using amino acids in blood, and thus completed the present invention.

[0013] That is, in order to solve the above-mentioned problems and achieve the object, the evaluation method of the present invention is characterized by including an evaluation step of evaluating the possibility of cancer recurrence in a subject in which cancer has been found, using concentration values ​​of at least one of 12 types of amino acids (Glu, Ser, a-ABA, Val, Met, Lys, Ile, Leu, Trp, His, Orn and Pro) or at least two of 21 types of amino acids (Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Trp, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA and Gly) in the blood of the subject in whom cancer has been found.

[0014] In this specification, various amino acids are mainly represented by abbreviations, but their formal names are as follows: (Abbreviation) (Formal name) Ala Alanine Arg Arginine Asparagine a-ABA α-Aminobutyric acid Cit Citrulline Gln Glutamine Glutamic acid Gly Glycine His Histidine Isoleucine Leu Leucine Lysine Methionine Orn Ornithine Phe Phenylalanine Proline Ser Serine Thr Threonine Trp Tryptophan Tyr Tyrosine Val Valine

[0015] Furthermore, the evaluation method of the present invention is characterized in that in the evaluation step, an equation including a variable into which concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids are substituted is further used to calculate the value of the equation, thereby evaluating the possibility of cancer recurrence for the evaluation subject.

[0016] Furthermore, the evaluation device of the present invention is characterized in that it is equipped with a control unit, and the control unit is equipped with evaluation means for evaluating the possibility of cancer recurrence in a subject in which cancer has been found, using concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids in the blood of the subject in whom cancer has been found.

[0017] Furthermore, the evaluation method of the present invention is an evaluation method executed in an information processing device equipped with a control unit, and is characterized by including an evaluation step executed in the control unit, of evaluating the possibility of cancer recurrence in a subject in whom cancer has been found, using concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids in the blood of the subject.

[0018] Furthermore, the evaluation program of the present invention is an evaluation program to be executed in an information processing device equipped with a control unit, and is characterized in that, to be executed in the control unit, it includes an evaluation step of evaluating the possibility of cancer recurrence in a subject in which cancer has been found, using concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids in the blood of the subject.

[0019] Furthermore, a recording medium according to the present invention is a non-transitory computer-readable recording medium, characterized in that it contains programmed instructions for causing an information processing device to execute the evaluation method.

[0020] Furthermore, the evaluation system of the present invention is an evaluation system configured by communicatively connecting, via a network, an evaluation device equipped with a control unit, and a terminal device equipped with a control unit and providing concentration data regarding the concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids in the blood of an evaluation subject in which cancer has been found, wherein the control unit of the terminal device comprises concentration data transmitting means for transmitting the concentration data to the evaluation device, and result receiving means for receiving an evaluation result regarding the possibility of cancer recurrence transmitted from the evaluation device, and the control unit of the evaluation device comprises concentration data receiving means for receiving the concentration data transmitted from the terminal device, evaluation means for evaluating the possibility of cancer recurrence of the evaluation subject using the concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids contained in the concentration data received by the concentration data receiving means, and result transmitting means for transmitting the evaluation result obtained by the evaluation means to the terminal device.

[0021] Furthermore, the terminal device of the present invention is a terminal device equipped with a control unit, and the control unit is characterized in that it has a result acquisition means for acquiring evaluation results regarding the possibility of cancer recurrence, and the evaluation results are a result of evaluating the possibility of cancer recurrence for the evaluation subject in which cancer has been found, using concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids in the blood of the evaluation subject in whom cancer has been found.

[0022] Furthermore, the terminal device of the present invention is configured to be communicatively connected via a network to an evaluation device that evaluates the possibility of cancer recurrence, and the control unit further comprises concentration data transmitting means for transmitting concentration data relating to concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids in the blood of the evaluation subject to the evaluation device, and the result obtaining means receives the evaluation results transmitted from the evaluation device.

[0023] Furthermore, the evaluation device of the present invention is an evaluation device equipped with a control unit that is communicatively connected via a network to a terminal device that provides concentration data regarding the concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids in the blood of an evaluation subject in whom cancer has been found, and the control unit is characterized in that it comprises: a concentration data receiving means that receives the concentration data transmitted from the terminal device; an evaluation means that evaluates the possibility of cancer recurrence for the evaluation subject using the concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids contained in the concentration data received by the concentration data receiving means; and a result transmitting means that transmits the evaluation results obtained by the evaluation means to the terminal device. Effect of the Invention

[0024] According to the present invention, there is an effect of providing highly reliable information that can be used as a reference for knowing the possibility of cancer recurrence, by utilizing blood amino acid concentrations. [Brief description of the drawings]

[0025] [Figure 1] FIG. 1 is a diagram showing the basic principle of the first embodiment. [Diagram 2] FIG. 2 is a diagram showing the basic principle of the second embodiment. [Diagram 3] FIG. 3 is a diagram showing an example of the overall configuration of the present system. [Figure 4]FIG. 4 is a diagram showing another example of the overall configuration of the present system. [Diagram 5] FIG. 5 is a block diagram showing an example of the configuration of the evaluation device 100 of this system. [Figure 6] FIG. 6 is a diagram showing an example of information stored in the concentration data file 106a. [Figure 7] FIG. 7 is a diagram showing an example of information stored in the index state information file 106b. [Figure 8] FIG. 8 is a diagram showing an example of information stored in the designated index state information file 106c. [Figure 9] FIG. 9 is a diagram showing an example of information stored in the formula file 106d1. [Figure 10] FIG. 10 is a diagram showing an example of information stored in the evaluation result file 106e. [Figure 11] FIG. 11 is a block diagram showing the configuration of the evaluation unit 102d. [Figure 12] FIG. 12 is a block diagram showing an example of the configuration of a client device 200 of this system. [Figure 13] FIG. 13 is a block diagram showing an example of the configuration of the database device 400 of this system. [Figure 14] FIG. 14 shows concentration data of 21 amino acids in non-relapse cases. [Figure 15] FIG. 15 shows concentration data of 21 amino acids in recurrent cases. [Figure 16] FIG. 16 is a radar chart showing "the distribution of each amino acid after surgery when each amino acid before surgery is set to 100%" for recurrence-free cases. [Figure 17] FIG. 17 is a diagram showing a radar chart showing "the distribution of each amino acid after surgery when each amino acid before surgery is set to 100%" for recurrent cases. [Figure 18] FIG. 18 shows the results of the logistic regression analysis. [Figure 19] FIG. 19 is a diagram showing combinations of two variables and the ROC_AUC for each combination. [Figure 20] FIG. 20 shows combinations of three variables and the ROC_AUC for each combination. [Figure 21] FIG. 21 shows combinations of four variables and the ROC_AUC for each combination. [Figure 22] FIG. 22 shows combinations of two variables and the ROC_AUC for each combination. [Diagram 23] FIG. 23 is a diagram showing combinations of three variables and the ROC_AUC for each combination. [Figure 24] FIG. 24 is a diagram showing combinations of four variables and the ROC_AUC for each combination. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] Hereinafter, an embodiment (first embodiment) of the evaluation method according to the present invention, and an embodiment (second embodiment) of the evaluation device, evaluation method, evaluation program, recording medium, evaluation system, and terminal device according to the present invention will be described in detail with reference to the drawings. Note that the present invention is not limited to these embodiments.

[0027] [First embodiment] [1-1. Overview of the first embodiment] Here, an overview of the first embodiment will be described with reference to Fig. 1. Fig. 1 is a diagram showing the basic principle of the first embodiment.

[0028] First, concentration data is obtained regarding the concentration values ​​of at least one of the 12 amino acids or at least two of the 21 amino acids in the blood (including, for example, plasma, serum, etc.) of a subject (for example, an individual such as an animal or human) in whom cancer has been found in the past (step S11).

[0029] Here, "cancer has been found" includes, for example, a definitive diagnosis of cancer. In step S11, for example, concentration data derived from blood collected from a subject in whom cancer has been found before treatment of the found cancer (for example, treatment by surgical therapy, chemotherapy, radiation therapy, or cancer immunotherapy) is started (concentration data before the start of treatment) and concentration data derived from blood collected after the start of the treatment (concentration data after the start of treatment) may be acquired. Note that "before treatment is started" includes, for example, before the first narrow-sense treatment in a broad-sense treatment over a certain period of time is performed, etc. In addition, "after treatment is started" includes, for example, after the first narrow-sense treatment in a broad-sense treatment over a certain period of time and before the final narrow-sense treatment is performed (for example, commonly referred to as "during treatment"), or after the final narrow-sense treatment in a broad-sense treatment over a certain period of time is performed (for example, commonly referred to as "after treatment").

[0030] In step S11, concentration data measured by a company or the like that measures concentration values ​​may be obtained. Concentration data may also be obtained by measuring the concentration value from blood collected from the subject to be evaluated using the following measurement method (A), (B), or (C), for example. Here, the unit of the concentration value may be, for example, molar concentration, weight concentration, or enzyme activity, or may be obtained by adding, subtracting, multiplying, or dividing any constant by these concentrations. (A) The collected blood samples are centrifuged to separate plasma from the blood. All plasma samples are frozen and stored at -80°C until the concentration values ​​are measured. When measuring the concentration values, acetonitrile is added to remove proteins, and then pre-column derivatization is performed using a labeling reagent (3-aminopyridyl-N-hydroxysuccinimidyl carbamate), and the concentration values ​​are analyzed by liquid chromatography mass spectrometry (LC / MS) (see WO 2003 / 069328 and WO 2005 / 116629). (B) The collected blood samples are centrifuged to separate plasma from the blood. All plasma samples are frozen and stored at -80°C until the concentration values ​​are measured. When measuring the concentration values, sulfosalicylic acid is added to remove proteins, and then the concentration values ​​are analyzed using an amino acid analyzer based on the post-column derivatization method using ninhydrin reagent. (C) The collected blood sample is subjected to blood cell separation using membranes, MEMS technology, or the principle of centrifugation to separate plasma or serum from the blood. Plasma or serum samples that are not subjected to concentration measurement immediately after plasma or serum collection are frozen and stored at -80°C until the concentration value is measured. When measuring the concentration value, molecules such as enzymes and aptamers that react with or bind to the target amino acids are used to analyze the concentration value by quantifying substances that increase or decrease due to substrate recognition or spectroscopic values.

[0031] Next, the possibility of cancer recurrence is evaluated for the evaluation subject using the concentration values ​​included in the concentration data acquired in step S11 (step S12). Note that before executing step S12, data such as missing values ​​and outliers may be removed from the concentration data acquired in step S11. Note that "recurrence" includes, for example, local recurrence, regional recurrence, and distant recurrence (metastasis). Note that "evaluating the possibility of cancer recurrence" includes, for example, evaluating the degree of possibility of cancer recurrence. Note that, when both concentration data before the start of treatment and concentration data after the start of treatment are used in step S12, for example, the ratio or difference between the concentration value before the start of treatment and the concentration value after the start of treatment may be calculated, and the evaluation may be performed using the calculated ratio or difference value.

[0032] As described above, in the first embodiment, in step S11, concentration data of the evaluation target is acquired, and in step S12, the concentration value included in the concentration data of the evaluation target acquired in step S11 is used to evaluate the possibility of cancer recurrence for the evaluation target (in other words, information for evaluating the possibility of cancer recurrence or highly reliable information that can be used as a reference for knowing the possibility of cancer recurrence is acquired). This allows the possibility of cancer recurrence to be accurately evaluated using blood amino acid concentrations (in other words, information for evaluating the possibility of cancer recurrence or highly reliable information that can be used as a reference for knowing the possibility of cancer recurrence can be provided). In particular, when only concentration data before the start of treatment is used in step S12, the evaluation result obtained in this embodiment can be used as reference information when determining a treatment method. In addition, when concentration data after the start of treatment or after treatment is used in step S12, the evaluation result obtained in this embodiment can be used for monitoring recurrence, can be used as reference information when determining a further treatment method, or can be used as reference information when selecting a period and means of postoperative follow-up.

[0033] Also, it may be determined that the concentration value (which may be the above-mentioned ratio or difference value) of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids reflects the possibility of cancer recurrence in the subject to be evaluated or is an index of the possibility of cancer recurrence in the subject to be evaluated, and further, the concentration value (which may be the above-mentioned ratio or difference value) may be converted, for example, by the method listed below, and the converted value may be determined to reflect the possibility of cancer recurrence in the subject to be evaluated or be an index of the possibility of cancer recurrence in the subject to be evaluated. In other words, the concentration value or the converted value itself may be treated as the evaluation result regarding the possibility of cancer recurrence in the subject to be evaluated. In order to make the possible range of the concentration value fall within a predetermined range (e.g., the range from 0.0 to 1.0, the range from 0.0 to 10.0, the range from 0.0 to 100.0, or the range from -10.0 to 10.0, etc.), the concentration value may be converted by, for example, adding, subtracting, multiplying, or dividing an arbitrary value to the concentration value, converting the concentration value using a predetermined conversion method (e.g., exponential conversion, logarithmic conversion, angular conversion, square root conversion, probit conversion, reciprocal conversion, Box-Cox conversion, or power conversion, etc.), or by combining these calculations on the concentration value. For example, the value of an exponential function with the concentration value as the exponent and Napier's number as the base (specifically, the value of p / (1-p) when the natural logarithm ln(p / (1-p)) when the probability p of cancer recurrence is defined is equal to the concentration value) may be further calculated, and the value of the calculated exponential function divided by the sum of 1 and the value (specifically, the value of the probability p) may be further calculated. The concentration values ​​may also be converted so that the converted values ​​under specific conditions are specific values, for example, the concentration values ​​may be converted so that the converted value is 5.0 when the specificity is 80% and the converted value is 8.0 when the specificity is 95%. In addition, the concentration distribution for each amino acid may be normalized, and then the distribution may be converted to a deviation value with an average of 50 and a standard deviation of 10. These conversions may be performed according to gender or age. In this specification, the density value may be the density value itself, or may be a value obtained by converting the density value.

[0034] In addition, position information regarding the position of a predetermined mark on a predetermined ruler that is visibly displayed on a display device such as a monitor or a physical medium such as paper may be generated using the concentration values ​​(which may be the above-mentioned ratio or difference values) of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids, or the converted values ​​if the concentration values ​​are converted, and the generated position information may be determined to reflect the possibility of cancer recurrence in the evaluation subject or to be an index of the possibility of cancer recurrence in the evaluation subject. The predetermined ruler is for evaluating the possibility of cancer recurrence, and is, for example, a ruler with a scale, which is at least a scale corresponding to the upper and lower limits in the "range in which the concentration value or the converted value can be taken, or a part of the range". The predetermined mark is, for example, a circle or a star, which corresponds to the concentration value or the converted value.

[0035] In addition, when the concentration value (which may be the above-mentioned ratio or difference value) of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids is lower than a predetermined value (such as the mean value ± 1SD, 2SD, 3SD, N quantile, N percentile, or a cutoff value recognized for clinical significance), or is equal to or higher than a predetermined value, the possibility of cancer recurrence in the subject may be evaluated. In this case, instead of the concentration value itself, a concentration deviation value (a value obtained by normalizing the concentration distribution for each metabolite and each amino acid by gender and then deviating the distribution to an average of 50 and a standard deviation of 10) may be used. For example, when the concentration deviation value is less than the mean value -2SD (when the concentration deviation value is <30) or when the concentration deviation value is higher than the mean value +2SD (when the concentration deviation value is >70), the possibility of cancer recurrence in the subject may be evaluated.

[0036] In addition, the possibility of cancer recurrence in the subject may be evaluated by calculating the value of a formula using a formula including concentration values ​​(which may be the ratio or difference values ​​described above) of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids and variables into which the concentration values ​​(which may be the ratio or difference values ​​described above) are substituted.

[0037] The calculated value of the formula may be determined to reflect the possibility of cancer recurrence in the subject or to be an index of the possibility of cancer recurrence in the subject, and the value of the formula may be converted, for example, by the methods listed below, and the converted value may be determined to reflect the possibility of cancer recurrence in the subject or to be an index of the possibility of cancer recurrence in the subject. In other words, the value of the formula or the converted value itself may be treated as the evaluation result regarding the possibility of cancer recurrence in the subject. In order to make the possible range of the value of the formula fall within a predetermined range (e.g., the range from 0.0 to 1.0, the range from 0.0 to 10.0, the range from 0.0 to 100.0, or the range from -10.0 to 10.0, etc.), for example, the value of the formula may be converted by adding, subtracting, multiplying, or dividing any value, converting the value of the formula using a predetermined conversion method (e.g., exponential conversion, logarithmic conversion, angular conversion, square root conversion, probit conversion, reciprocal conversion, Box-Cox conversion, or power conversion, etc.), or by combining these calculations on the value of the formula. For example, the value of an exponential function with the value of the formula as the exponent and Napier's number as the base (specifically, the value of p / (1-p) when the natural logarithm ln(p / (1-p)) when the probability p of cancer recurrence is defined is equal to the value of the formula) may be further calculated, and the value of the calculated exponential function divided by the sum of 1 and the value (specifically, the value of the probability p) may be further calculated. The value of the formula may also be converted so that the converted value under a particular condition is a particular value, for example, the converted value may be 5.0 when the specificity is 80% and 8.0 when the specificity is 95%. The formula values ​​may also be converted to standard deviation values ​​with an average of 50 and a standard deviation of 10. These conversions may be performed according to gender or age. In this specification, the value of an expression may be the value of the expression itself, or may be a value obtained after the value of the expression is converted.

[0038] In addition, position information regarding the position of a predetermined mark on a predetermined ruler that is visibly displayed on a display device such as a monitor or a physical medium such as paper may be generated using the value of the formula or, if the value of the formula is converted, the converted value, and it may be determined that the generated position information reflects the possibility of cancer recurrence in the subject to be evaluated or is an index of the possibility of cancer recurrence in the subject to be evaluated. The predetermined ruler is for evaluating the possibility of cancer recurrence, and is, for example, a ruler with a scale, which at least indicates the upper and lower limit values ​​in the "range in which the value of the formula or the converted value can be taken, or a part of the range". The predetermined mark is, for example, a circle or a star, which corresponds to the value of the formula or the converted value.

[0039] The degree of possibility of cancer recurrence in the subject may be qualitatively evaluated. Specifically, the subject may be classified into one of a plurality of categories defined by at least considering the degree of possibility of cancer recurrence using "at least one of the 12 types of amino acids or at least two of the 21 types of amino acids (which may be the above-mentioned ratio or difference value) and one or more preset thresholds" or "at least one of the 12 types of amino acids or at least two of the 21 types of amino acids (which may be the above-mentioned ratio or difference value), an equation including a variable into which the concentration value (which may be the above-mentioned ratio or difference value) is substituted, and one or more preset thresholds." The plurality of categories may include a category for subjects with a high degree of possibility of cancer recurrence (e.g., subjects considered to have cancer recurrence), a category for subjects with a low degree of possibility of cancer recurrence (e.g., subjects considered not to have cancer recurrence), and a category for subjects with a medium degree of possibility of cancer recurrence. The multiple categories may include a category for subjects with a high possibility of cancer recurrence and a category for subjects with a low possibility of cancer recurrence. The concentration value (which may be the above-mentioned ratio or difference value) or the value of the formula may be converted by a predetermined method, and the converted value may be used to classify the evaluation subject into one of the multiple categories.

[0040] The formula used for the evaluation can be in any format, but may be, for example, in the format shown below. Linear models such as multiple regression equations based on the least squares method, linear discriminants, principal component analysis, and canonical discriminant analysis Generalized linear models such as maximum likelihood logistic regression and Cox regression -Generalized linear mixed model that considers random effects such as individual differences and facility differences in addition to generalized linear models · Equations created by cluster analysis such as K-means and hierarchical cluster analysis Formulas based on Bayesian statistics such as MCMC (Markov Chain Monte Carlo), Bayesian Networks, and Hierarchical Bayesian methods - Formulas created by class classification such as support vector machines and decision trees Formulas created using methods that do not fall into the above categories, such as fractional formulas An equation that can be expressed as a sum of different forms of equations

[0041] Furthermore, the formula used in the evaluation may be prepared, for example, by the method described in International Publication No. WO 2004 / 052191, an international application filed by the present applicant, or the method described in International Publication No. WO 2006 / 098192, an international application filed by the present applicant. Note that, if the formula is obtained by these methods, the formula can be suitably used for evaluating the possibility of cancer recurrence, regardless of the unit of the amino acid concentration value in the concentration data as input data.

[0042] Here, in the multiple regression equation, multiple logistic regression equation, canonical discriminant function, etc., a coefficient and a constant term are added to each variable, and these coefficients and constant terms may be preferably real numbers, more preferably values ​​within the range of the 99% confidence interval of the coefficients and constant terms obtained for performing the various classifications from the data, and even more preferably values ​​within the range of the 95% confidence interval of the coefficients and constant terms obtained for performing the various classifications from the data. In addition, the value of each coefficient and its confidence interval may be multiplied by a real number, and the value of the constant term and its confidence interval may be added, subtracted, multiplied, or divided by an arbitrary real constant. When a logistic regression equation, a linear discriminant, a multiple regression equation, etc. are used for evaluation, linear transformation (addition of a constant, constant multiplication) and monotonically increasing (decreasing) transformation (for example, logit transformation, etc.) do not change the evaluation performance and are equivalent to the one before the transformation, so that the one after these transformations may be used for evaluation.

[0043] A fractional expression is one in which the numerator is expressed as the sum of the variables A, B, C, ... and / or the denominator is expressed as the sum of the variables a, b, c, .... Fractional expressions also include sums of fractional expressions of this type, α, β, γ, ... (such as α + β). Fractional expressions also include divided fractional expressions. The variables used in the numerator and denominator may each have an appropriate coefficient. The variables used in the numerator and denominator may also be duplicated. Each fractional expression may have an appropriate coefficient. The values ​​of the coefficients of each variable and the values ​​of the constant terms may be real numbers. In addition, although the positive / negative sign of the correlation with the objective variable is generally reversed between a fractional formula and one in which the numerator variable and denominator variable have been swapped, the correlation is maintained and the evaluation performance can be considered to be equivalent, so fractional formulas also include those in which the numerator variable and denominator variable have been swapped.

[0044] Furthermore, when evaluating the possibility of cancer recurrence, biological information other than amino acids (for example, blood metabolites other than amino acids (amino acid metabolites, sugars, lipids, etc.), concentrations of proteins, peptides, minerals, hormones, etc., tumor marker values, blood test values ​​such as albumin, total protein, triglycerides, HbA1c, LDL cholesterol, HDL cholesterol, amylase, total bilirubin, uric acid, etc., immune-related test values ​​such as blood cytokines, immune cell count, immune intracellular cytokines, or delayed type hyperresponsiveness (DTH), image information such as ultrasound echo, upper and lower endoscopy, X-ray, CT, or MRI, or biological indicators such as age, height, weight, BMI, blood pressure, sex, smoking information, dietary information, alcohol drinking information, exercise information, stress information, sleep information, family medical history information, or disease history information (diabetes, pancreatitis, etc.)) may also be used. Furthermore, variables in a formula (e.g., a multivariate discriminant) used in the evaluation may further include biological information other than amino acids (e.g., concentrations of blood metabolites other than amino acids (amino acid metabolites, sugars, lipids, etc.), proteins, peptides, minerals, hormones, etc., tumor marker values, blood test values ​​such as albumin, total protein, triglycerides, HbA1c, LDL cholesterol, HDL cholesterol, amylase, total bilirubin, uric acid, etc., immune-related test values ​​such as blood cytokines, immune cell count, immune intracellular cytokines, or delayed type hyperresponsiveness (DTH), image information such as ultrasound echo, upper and lower endoscopy, X-ray, CT, or MRI, or biological indicators such as age, height, weight, BMI, blood pressure, sex, smoking information, dietary information, drinking information, exercise information, stress information, sleep information, family medical history information, or disease history information (diabetes, pancreatitis, etc.)).

[0045] [Second embodiment] [2-1. Overview of the second embodiment] Here, an overview of the second embodiment will be described with reference to FIG. 2. FIG. 2 is a diagram showing the basic principle of the second embodiment. In the description of the second embodiment, explanations that overlap with those of the first embodiment may be omitted. In particular, a case in which the value of the formula or a value after conversion thereof is used when evaluating the possibility of cancer recurrence is described here as an example, but for example, a concentration value, a ratio of concentration values, or a difference between concentration values, or a value after conversion thereof (for example, a concentration deviation value, etc.) may also be used.

[0046] The control unit evaluates the possibility of cancer recurrence for the evaluation subject by calculating the value of a formula using a formula stored in advance in the storage unit that includes a concentration value included in previously acquired concentration data regarding at least one of the 12 types of amino acids or at least two of the 21 types of amino acids in the blood of the evaluation subject (e.g., an individual such as an animal or human) in which cancer has been found, and a variable into which the concentration value is substituted (step S21). Note that, when both the concentration data before the start of treatment and the concentration data after the start of treatment are used in step S21, the control unit may, for example, calculate the ratio or difference between the concentration value before the start of treatment and the concentration value after the start of treatment, and calculate the value of the formula by substituting the calculated ratio or difference value into the variable to evaluate the possibility of cancer recurrence for the evaluation subject.

[0047] The formula used in step S21 may be one created based on the formula creation process (steps 1 to 4) described below. Here, an overview of the formula creation process will be described. Note that the process described here is merely an example, and the formula creation method is not limited to this.

[0048] First, the control unit creates a candidate formula (e.g., y=a1x1+a2x2+···+anxn, where y is index data, xi is concentration data, ai is a constant, i=1,2,···,n) from index state information previously stored in the storage unit (which may be data from which data having missing values ​​or outliers has been removed in advance) based on a predetermined formula creation method (step 1). Note that the index state information includes concentration data (e.g., preoperative data on amino acid concentration, postoperative data on amino acid concentration, or data on the amount of change in amino acid concentration between preoperative and postoperative, etc.) and index data on cancer recurrence (e.g., binary data on the presence or absence of recurrence, etc.).

[0049] In step 1, multiple candidate formulas may be created from the index state information by using multiple different formula creation methods (including those related to multivariate analysis such as principal component analysis, discriminant analysis, support vector machine, multiple regression analysis, Cox regression analysis, logistic regression analysis, k-means method, cluster analysis, and decision tree). Specifically, multiple groups of candidate formulas may be created simultaneously in parallel using multiple different algorithms for index state information, which is multivariate data composed of concentration data and index data obtained by analyzing blood obtained before and / or after surgery from a large number of recurrence groups and non-recurrence groups. For example, two different candidate formulas may be created by simultaneously performing discriminant analysis and logistic regression analysis using different algorithms. In addition, the index state information may be converted using a candidate formula created by performing principal component analysis, and a discriminant analysis may be performed on the converted index state information to create a candidate formula. This allows the creation of a formula optimal for evaluation.

[0050] Here, the candidate formula created using principal component analysis is a linear formula including each variable that maximizes the variance of all concentration data. Also, the candidate formula created using discriminant analysis is a high-order formula (including exponential and logarithmic) including each variable that minimizes the ratio of the sum of variances in each group to the variance of all concentration data. Also, the candidate formula created using support vector machine is a high-order formula (including kernel function) including each variable that maximizes the boundary between groups. Also, the candidate formula created using multiple regression analysis is a high-order formula including each variable that minimizes the sum of distances from all concentration data. Also, the candidate formula created using Cox regression analysis is a linear model including a log hazard ratio, and is a linear formula including each variable and its coefficient that maximizes the likelihood of the model. Also, the candidate formula created using logistic regression analysis is a linear model that represents the log odds of probability, and is a linear formula including each variable that maximizes the likelihood of the probability. The k-means method is a method that searches k neighbors of each concentration data, defines the group to which the most neighboring points belong as the group to which the data belongs, and selects the variable that best matches the defined group to which the input concentration data belongs. Cluster analysis is a method of clustering (grouping) points that are closest to each other among all concentration data. A decision tree is a method of ranking variables and predicting groups of concentration data from the possible patterns of variables with higher rankings.

[0051] Returning to the explanation of the formula creation process, the control unit verifies (cross-validates) the candidate formulas created in step 1 based on a predetermined verification method (step 2). The candidate formulas are verified for each candidate formula created in step 1. In step 2, at least one of the discrimination rate, sensitivity, specificity, information criterion, ROC_AUC (area under the receiver characteristic curve), etc. of the candidate formula may be verified based on at least one of the bootstrap method, hold-out method, N-fold method, leave-one-out method, etc. This makes it possible to create a candidate formula with high predictability or robustness that takes into account index state information and evaluation conditions.

[0052] Here, the discrimination rate is the rate at which the evaluation method according to the present embodiment correctly evaluates evaluation objects whose true state is negative (e.g., evaluation objects whose true state is non-recurrence) as negative and correctly evaluates evaluation objects whose true state is positive (e.g., evaluation objects whose true state is recurrence) as positive. The sensitivity is the rate at which the evaluation method according to the present embodiment correctly evaluates evaluation objects whose true state is positive as positive. The specificity is the rate at which the evaluation method according to the present embodiment correctly evaluates evaluation objects whose true state is negative as negative. The Akaike information criterion is a standard that indicates the degree to which observed data matches a statistical model in the case of regression analysis, etc., and the model that has the smallest value defined as "-2 x (maximum logarithmic likelihood of the statistical model) + 2 x (number of free parameters of the statistical model)" is judged to be the best. ROC_AUC is defined as the area under the receiver characteristic curve (ROC), which is a curve created by plotting (x, y) = (1 - specificity, sensitivity) on a two-dimensional coordinate system, and the ROC_AUC value is 1 for perfect discrimination, with the closer this value is to 1 the higher the discrimination ability. Predictability is the average of the discrimination rate, sensitivity, and specificity obtained by repeatedly verifying the candidate formula. Robustness is the variance of the discrimination rate, sensitivity, and specificity obtained by repeatedly verifying the candidate formula.

[0053] Returning to the explanation of the formula creation process, the control unit selects a combination of concentration data included in the index state information used when creating the candidate formula by selecting variables of the candidate formula based on a predetermined variable selection method (step 3). In step 3, variable selection may be performed for each candidate formula created in step 1. This allows the variables of the candidate formula to be appropriately selected. Then, step 1 is executed again using the index state information including the concentration data selected in step 3. In step 3, the variables of the candidate formula may be selected based on at least one of the stepwise method, the best path method, the neighborhood search method, and the genetic algorithm from the verification result in step 2. In addition, the best path method is a method of selecting variables by sequentially reducing the variables included in the candidate formula one by one and optimizing the evaluation index given by the candidate formula.

[0054] Returning to the explanation of the formula creation process, the control unit repeatedly executes the above-mentioned steps 1, 2, and 3, and creates a formula to be used in evaluation by selecting a candidate formula to be used in evaluation from among multiple candidate formulas based on the verification results accumulated thereby (step 4). Note that the selection of the candidate formula may involve, for example, selecting the optimal one from among candidate formulas created using the same formula creation method, or selecting the optimal one from among all candidate formulas.

[0055] As described above, in the formula creation process, the processes related to the creation of candidate formulas, the verification of the candidate formulas, and the selection of variables for the candidate formulas are systematized (systemized) in a series of flows and executed based on the index state information, thereby creating a formula optimal for evaluating the possibility of cancer recurrence. In other words, in the formula creation process, the concentration of at least one of the above 21 types of amino acids is used in multivariate statistical analysis, and a formula with high evaluation performance is extracted by combining a variable selection method and cross-validation to select an optimal and robust set of variables.

[0056] [2-2. Configuration of the second embodiment] Here, the configuration of the evaluation system according to the second embodiment (hereinafter, sometimes referred to as the present system) will be described with reference to Figs. 3 to 14. Note that the present system is merely an example, and the present invention is not limited thereto. In particular, a case in which the value of a formula or a value after conversion thereof is used when evaluating the possibility of cancer recurrence is described here as an example, but for example, a concentration value, a ratio of concentration values, or a difference between concentration values, or a value after conversion thereof (e.g., a concentration deviation value, etc.) may also be used.

[0057] First, the overall configuration of the present system will be described with reference to Figs. 3 and 4. Fig. 3 is a diagram showing an example of the overall configuration of the present system. Fig. 4 is a diagram showing another example of the overall configuration of the present system. As shown in Fig. 3, the present system is configured by communicatively connecting an evaluation device 100 for evaluating the possibility of cancer recurrence for an individual to be evaluated and a client device 200 (corresponding to a terminal device of the present invention) for providing individual concentration data on at least one of the 12 types of amino acids or at least two of the 21 types of amino acids in blood via a network 300. In this system, the client device 200 that is the source of data used in the evaluation and the client device 200 that is the destination of the evaluation results may be separate. As shown in Fig. 4, the present system may be configured by communicatively connecting a database device 400 that stores index state information used in creating a formula used in the evaluation and a formula used in the evaluation via the network 300 in addition to the evaluation device 100 and the client device 200.

[0058] Next, the configuration of the evaluation device 100 of this system will be described with reference to Fig. 5 to Fig. 11. Fig. 5 is a block diagram showing an example of the configuration of the evaluation device 100 of this system, and conceptually shows only the parts of the configuration that are related to the present invention.

[0059] The evaluation device 100 is composed of a control unit 102 such as a CPU (Central Processing Unit) that controls the evaluation device in an integrated manner, a communication interface unit 104 that communicatively connects the evaluation device to a network 300 via a communication device such as a router and a wired or wireless communication line such as a dedicated line, a storage unit 106 that stores various databases, tables, files, etc., and an input / output interface unit 108 that connects to an input device 112 and an output device 114, and these units are communicatively connected via any communication path. Here, the evaluation device 100 may be composed in the same housing as various analyzers (e.g., amino acid analyzers, etc.). For example, a small analyzer having a configuration (hardware and software) that calculates (measures) the concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids in blood and outputs the calculated values ​​(printing, displaying on a monitor, etc.) may further include an evaluation unit 102d described later, and the results obtained by the evaluation unit 102d may be output using the configuration.

[0060] The communication interface unit 104 mediates communication between the evaluation device 100 and the network 300 (or a communication device such as a router). That is, the communication interface unit 104 has a function of communicating data with other terminals via a communication line.

[0061] The input / output interface unit 108 is connected to an input device 112 and an output device 114. Here, the output device 114 may be a monitor (including a home television), a speaker, or a printer (hereinafter, the output device 114 may be referred to as a monitor 114). The input device 112 may be a keyboard, a mouse, a microphone, or a monitor that cooperates with a mouse to realize a pointing device function.

[0062] The memory unit 106 is a storage means, and may be, for example, a memory device such as a RAM (Random Access Memory) or a ROM (Read Only Memory), a fixed disk device such as a hard disk, a flexible disk, an optical disk, etc. The memory unit 106 records computer programs for cooperating with an OS (Operating System) to give instructions to a CPU to perform various processes. As shown in the figure, the memory unit 106 stores a concentration data file 106a, an index state information file 106b, a specified index state information file 106c, a formula related information database 106d, and an evaluation result file 106e.

[0063] The concentration data file 106a stores concentration data (for example, either one or both of concentration data before the start of treatment and concentration data after the start of treatment) on the concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids in blood. FIG. 6 is a diagram showing an example of information stored in the concentration data file 106a. As shown in FIG. 6, the information stored in the concentration data file 106a is configured by correlating individual numbers for uniquely identifying individuals (samples) to be evaluated with concentration data. Here, in FIG. 6, the concentration data is treated as a numerical value, i.e., a continuous scale, but the concentration data may be a nominal scale or an ordinal scale. In the case of a nominal scale or an ordinal scale, an arbitrary numerical value may be assigned to each state for analysis. In addition, the concentration data may be combined with values ​​related to the above-mentioned biological information other than amino acids.

[0064] Returning to FIG. 5, the index state information file 106b stores index state information used when creating an equation. FIG. 7 is a diagram showing an example of information stored in the index state information file 106b. As shown in FIG. 7, the information stored in the index state information file 106b is configured by associating individual numbers, index data related to cancer recurrence, and concentration data with each other. Here, in FIG. 7, the index data and concentration data are treated as numerical values ​​(i.e., continuous scale), but the index data and concentration data may be nominal or ordinal scales. In the case of nominal or ordinal scales, analysis may be performed by assigning arbitrary numerical values ​​to each state.

[0065] Returning to Fig. 5, the specified index status information file 106c stores index status information specified by the specification unit 102b, which will be described later. Fig. 8 is a diagram showing an example of information stored in the specified index status information file 106c. As shown in Fig. 8, the information stored in the specified index status information file 106c is configured by associating individual numbers, specified index data, and specified concentration data with each other.

[0066] Returning to Fig. 5, the formula-related information database 106d is composed of a formula file 106d1 that stores formulas created by the formula creation unit 102c described later. The formula file 106d1 stores formulas used in evaluation. Fig. 9 is a diagram showing an example of information stored in the formula file 106d1. As shown in Fig. 9, the information stored in the formula file 106d1 is composed of ranks, formulas (Fp(Phe,···), Fp(Gly,Leu,Phe), Fk(Gly,Leu,Phe,···), etc. in Fig. 9), thresholds corresponding to each formula creation method, and verification results of each formula (for example, the value of each formula) that are mutually associated with each other.

[0067] Returning to Fig. 5, the evaluation result file 106e stores the evaluation results obtained by the evaluation unit 102d described later. Fig. 10 is a diagram showing an example of information stored in the evaluation result file 106d. The information stored in the evaluation result file 106d is configured by associating an individual number for uniquely identifying an individual (sample) to be evaluated, individual concentration data acquired in advance, and an evaluation result regarding the possibility of cancer recurrence (for example, a value of a formula calculated by a calculation unit 102d1 described later, a value obtained by converting the value of a formula by a conversion unit 102d2 described later, position information generated by a generation unit 102d3 described later, or a classification result obtained by a classification unit 102d4 described later, etc.) with each other.

[0068] Returning to Fig. 5, the control unit 102 has an internal memory for storing control programs such as an OS, programs that define various processing procedures, required data, etc., and executes various information processing based on these programs. As shown in the figure, the control unit 102 is roughly equipped with a receiving unit 102a, a designating unit 102b, a formula creating unit 102d, an evaluating unit 102e, a result output unit 102e, and a transmitting unit 102f. The control unit 102 also performs data processing such as removing data with missing values, removing data with many outliers, and removing variables with many data with missing values ​​for the index state information transmitted from the database device 400 and the concentration data transmitted from the client device 200.

[0069] The receiving unit 102a may receive information (specifically, concentration data, index state information, a formula, etc.) transmitted from the client device 200 or the database device 400 via the network 300. The receiving unit 102a may receive data used for evaluation transmitted from a client device 200 different from the client device 200 to which the evaluation result is transmitted. The designation unit 102b designates the index data and concentration data to be targeted when creating a formula.

[0070] The equation creation unit 102c creates an equation based on the index state information received by the receiving unit 102a and the index state information designated by the designation unit 102b. When an equation is stored in advance in a predetermined storage area of ​​the storage unit 106, the equation creation unit 102c may create an equation by selecting a desired equation from the storage unit 106. The equation creation unit 102c may also create an equation by selecting a desired equation from another computer device (e.g., database device 400) that has equations stored in advance and downloading the equation.

[0071] The evaluation unit 102d evaluates the possibility of cancer recurrence for the individual by calculating the value of the formula using a formula obtained in advance (e.g., a formula created by the formula creation unit 102c or a formula received by the receiving unit 102a) and the concentration values ​​included in the individual's concentration data received by the receiving unit 102a. The evaluation unit 102d may evaluate the possibility of cancer recurrence for the individual by using the concentration values, the ratio of the concentration values, or the difference of the concentration values ​​of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids, or the values ​​after conversion of these (e.g., concentration deviation values).

[0072] Here, the configuration of the evaluation unit 102d will be described with reference to Fig. 11. Fig. 11 is a block diagram showing the configuration of the evaluation unit 102d, and conceptually shows only the parts of the configuration related to the present invention. The evaluation unit 102d further includes a calculation unit 102d1, a conversion unit 102d2, a generation unit 102d3, and a classification unit 102d4.

[0073] The calculation unit 102d1 calculates the value of the formula using a formula including at least a concentration value (which may be the above-mentioned ratio or difference value) of at least one of the 12 types of amino acids or at least two of the 21 types of amino acids and a variable into which the concentration value is substituted. The evaluation unit 102d may store the value of the formula calculated by the calculation unit 102d1 as the evaluation result in a predetermined storage area of ​​the evaluation result file 106e.

[0074] The conversion unit 102d2 converts the value of the formula calculated by the calculation unit 102d1, for example, using the conversion method described above. The evaluation unit 102d may store the value converted by the conversion unit 102d2 in a predetermined storage area of ​​the evaluation result file 106e as the evaluation result. The conversion unit 102d2 may also convert the concentration value included in the concentration data or the ratio or difference of the concentration values, for example, using the conversion method described above.

[0075] The generating unit 102d3 generates position information on the position of a predetermined mark on a predetermined ruler that is visibly shown on a display device such as a monitor or a physical medium such as paper, using the value of the formula calculated by the calculating unit 102d1 or the value after conversion by the converting unit 102d2 (which may be a concentration value, a ratio of concentration values, a difference of concentration values, or a value after conversion of these). Note that the evaluating unit 102d may store the position information generated by the generating unit 102d3 in a predetermined storage area of ​​the evaluation result file 106e as an evaluation result.

[0076] The classification unit 102d4 uses the value of the formula calculated by the calculation unit 102d1 or the value after conversion by the conversion unit 102d2 (which may be a concentration value, a ratio of concentration values, a difference of concentration values, or a value after these conversions) to classify the individual into one of a plurality of categories defined taking into consideration at least the degree of possibility of cancer recurrence.

[0077] The result output unit 102e outputs to the output device 114 the processing results of each processing unit in the control unit 102 (including the evaluation result obtained by the evaluation unit 102d) and the like.

[0078] The transmission unit 102f transmits the evaluation result to the client device 200 that transmitted the concentration data of the individual, and transmits the formula created by the evaluation device 100 and the evaluation result to the database device 400. The transmission unit 102f may transmit the evaluation result to a client device 200 different from the client device 200 that transmitted the data used for the evaluation.

[0079] Next, the configuration of client device 200 of this system will be described with reference to Fig. 12. Fig. 12 is a block diagram showing an example of the configuration of client device 200 of this system, and conceptually shows only the parts of the configuration that are related to the present invention.

[0080] The client device 200 is composed of a control unit 210, a ROM 220, a HD (Hard Disk) 230, a RAM 240, an input device 250, an output device 260, an input / output IF 270, and a communication IF 280, and these units are communicably connected via any communication path. The client device 200 may be based on an information processing device (for example, a known information processing terminal such as a personal computer, a workstation, a home game device, an Internet TV, a PHS (Personal Handyphone System) terminal, a mobile terminal, a mobile communication terminal, a PDA (Personal Digital Assistant), etc.) to which peripheral devices such as a printer, a monitor, an image scanner, etc. are connected as necessary.

[0081] The input device 250 is a keyboard, a mouse, a microphone, etc. A monitor 261, which will be described later, also realizes a pointing device function in cooperation with a mouse. The output device 260 is an output means for outputting information received via the communication IF 280, and includes a monitor (including a home television) 261 and a printer 262. In addition, the output device 260 may be provided with a speaker, etc. The input / output IF 270 is connected to the input device 250 and the output device 260.

[0082] The communication IF 280 communicatively connects the client device 200 and the network 300 (or a communication device such as a router). In other words, the client device 200 is connected to the network 300 via a communication device such as a modem, a TA (Terminal Adapter), or a router and a telephone line, or via a dedicated line. This allows the client device 200 to access the evaluation device 100 in accordance with a predetermined communication protocol.

[0083] The control unit 210 includes a receiving unit 211 and a transmitting unit 212. The receiving unit 211 receives various information such as the evaluation result transmitted from the evaluation device 100 via the communication IF 280. The transmitting unit 212 transmits various information such as the concentration data of the individual to the evaluation device 100 via the communication IF 280.

[0084] The control unit 210 may realize all or any part of the processing performed by the control unit with a CPU and a program that is interpreted and executed by the CPU. A computer program for giving instructions to the CPU in cooperation with the OS and performing various processing is recorded in the ROM 220 or the HD 230. The computer program is executed by being loaded into the RAM 240, and constitutes the control unit 210 in cooperation with the CPU. The computer program may also be recorded in an application program server connected to the client device 200 via any network, and the client device 200 may download all or any part of the computer program as necessary. Also, all or any part of the processing performed by the control unit 210 may be realized by hardware such as wired logic.

[0085] Here, the control unit 210 may include an evaluation unit 210a (including a calculation unit 210a1, a conversion unit 210a2, a generation unit 210a3, and a classification unit 210a4) having the same functions as those of the evaluation unit 102d included in the evaluation device 100. When the control unit 210 includes the evaluation unit 210a, the evaluation unit 210a may convert the value of the formula (which may be a concentration value, a ratio of concentration values, or a difference in concentration values) in the conversion unit 210a2, generate position information corresponding to the value of the formula or the converted value (which may be a concentration value, a ratio of concentration values, a difference in concentration values, or a value after conversion thereof) in the generation unit 210a3, or classify the individual into one of a plurality of categories using the value of the formula or the converted value (which may be a concentration value, a ratio of concentration values, a difference in concentration values, or a value after conversion thereof) in the classification unit 210a4, depending on the information included in the evaluation result transmitted from the evaluation device 100.

[0086] Next, the network 300 of this system will be described with reference to Figures 3 and 4. The network 300 has a function of connecting the evaluation device 100, the client device 200, and the database device 400 so that they can communicate with each other, and is, for example, the Internet, an intranet, or a LAN (Local Area Network) (including both wired and wireless networks). In addition, network 300 may be a VAN (Value-Added Network), a personal computer communication network, a public telephone network (including both analog and digital), a leased line network (including both analog and digital), a CATV (Community Antenna TeleVision) network, a mobile circuit-switched network or a mobile packet-switched network (including the IMT (International Mobile Telecommunication) 2000 system, the GSM (registered trademark) (Global System for Mobile Communications) system, or the PDC (Personal Digital Cellular) / PDC-P system, etc.), a radio paging network, a local wireless network such as Bluetooth (registered trademark), a PHS network, or a satellite communication network (including CS (Communication Satellite), BS (Broadcasting Satellite), or ISDB (Integrated Services Digital Broadcasting), etc.).

[0087] Next, the configuration of the database device 400 of this system will be described with reference to Fig. 13. Fig. 13 is a block diagram showing an example of the configuration of the database device 400 of this system, and conceptually shows only the parts of the configuration that are related to the present invention.

[0088] The database device 400 has a function of storing index state information used when creating an equation in the evaluation device 100 or the database device itself, an equation created in the evaluation device 100, an evaluation result in the evaluation device 100, etc. As shown in Fig. 13, the database device 400 is composed of a control unit 402 such as a CPU that controls the database device in an overall manner, a communication interface unit 404 that communicatively connects the database device to the network 300 via a communication device such as a router and a wired or wireless communication circuit such as a dedicated line, a storage unit 406 that stores various databases, tables, files (e.g., files for Web pages), etc., and an input / output interface unit 408 that connects to an input device 412 and an output device 414, and these units are communicatively connected via any communication path.

[0089] The memory unit 406 is a storage means, and may be, for example, a memory device such as a RAM or ROM, a fixed disk device such as a hard disk, a flexible disk, an optical disk, or the like. The memory unit 406 stores various programs and the like used for various processes. The communication interface unit 404 mediates communication between the database device 400 and the network 300 (or a communication device such as a router). That is, the communication interface unit 404 has a function of communicating data with other terminals via a communication line. The input / output interface unit 408 is connected to an input device 412 and an output device 414. Here, the output device 414 may be a monitor (including a home television), a speaker, or a printer. The input device 412 may be a keyboard, a mouse, a microphone, or a monitor that cooperates with a mouse to realize a pointing device function.

[0090] The control unit 402 has an internal memory for storing control programs such as an OS, programs defining various processing procedures, required data, etc., and executes various information processing based on these programs. As shown in the figure, the control unit 402 is roughly equipped with a transmission unit 402a and a reception unit 402b. The transmission unit 402a transmits various information such as index state information and equations to the evaluation device 100. The reception unit 402b receives various information such as equations and evaluation results transmitted from the evaluation device 100.

[0091] In this description, an example has been given in which the evaluation device 100 receives concentration data, calculates the value of the formula, classifies the individuals into categories, and transmits the evaluation results, while the client device 200 receives the evaluation results. However, if the client device 200 is equipped with the evaluation unit 210a, it is sufficient for the evaluation device 100 to calculate the value of the formula. For example, the conversion of the value of the formula, the generation of position information, and the classification of the individuals into categories may be appropriately shared between the evaluation device 100 and the client device 200. For example, when the client device 200 receives a value of an equation from the evaluation device 100, the evaluation unit 210a may convert the value of the equation in the conversion unit 210a2, generate position information corresponding to the value of the equation or the converted value in the generation unit 210a3, and classify the individual into one of a plurality of categories using the value of the equation or the converted value in the classification unit 210a4. Furthermore, when the client device 200 receives a converted value from the evaluation device 100, the evaluation unit 210a may generate position information corresponding to the converted value in the generation unit 210a3, or classify the individual into one of a plurality of categories using the converted value in the classification unit 210a4. In addition, when the client device 200 receives the value of the formula or the converted value and location information from the evaluation device 100, the evaluation unit 210a may classify the individual into one of a plurality of categories using the value of the formula or the converted value in the classification unit 210a4.

[0092] [2-3. Other embodiments] The evaluation device, evaluation method, evaluation program, evaluation system, and terminal device of the present invention may be embodied in various different embodiments other than the second embodiment described above, within the scope of the technical idea described in the claims.

[0093] Furthermore, among the processes described in the second embodiment, all or part of the processes described as being performed automatically can be performed manually, or all or part of the processes described as being performed manually can be performed automatically using known methods.

[0094] In addition, the processing procedures, control procedures, specific names, registered data for each process, information including parameters such as search conditions, screen examples, and database configurations shown in the above documents and drawings can be changed as desired unless otherwise specified.

[0095] Moreover, with regard to the evaluation device 100, the components shown in the figures are merely functional concepts, and the evaluation device 100 does not necessarily have to be physically configured as shown in the figures.

[0096] For example, the processing functions of the evaluation device 100, particularly the processing functions performed by the control unit 102, may be realized in whole or in part by a CPU and a program interpreted and executed by the CPU, or may be realized as hardware using wired logic. The program is recorded in a non-transient computer-readable recording medium including programmed instructions for causing an information processing device to execute the evaluation method according to the present invention, and is mechanically read by the evaluation device 100 as necessary. That is, a computer program for giving instructions to the CPU in cooperation with the OS and performing various processes is recorded in the storage unit 106 such as a ROM or HDD (Hard Disk Drive). This computer program is executed by being loaded into a RAM, and cooperates with the CPU to form a control unit.

[0097] In addition, this computer program may be stored in an application program server connected to the evaluation device 100 via any network, and it is also possible to download all or part of it as necessary.

[0098] The evaluation program according to the present invention may be stored in a non-transitory computer-readable recording medium, or may be configured as a program product. Here, the term "recording medium" includes any "portable physical medium" such as a memory card, a Universal Serial Bus (USB) memory, a Secure Digital (SD) card, a flexible disk, a magneto-optical disk, a ROM, an Erasable Programmable Read Only Memory (EPROM), an Electrically Erasable and Programmable Read Only Memory (EEPROM) (registered trademark), a Compact Disc Read Only Memory (CD-ROM), a Magneto-Optical disk (MO), a Digital Versatile Disk (DVD), and a Blu-ray (registered trademark) Disc.

[0099] Moreover, a "program" is a data processing method written in any language or description method, and may be in any form, such as source code or binary code. Note that a "program" is not necessarily limited to a single configuration, but also includes a distributed configuration as multiple modules or libraries, and a program that works with a separate program, such as an OS, to achieve its function. Note that the specific configuration and reading procedure for reading a recording medium in each device shown in the embodiments, as well as the installation procedure after reading, may use well-known configurations and procedures.

[0100] The various databases etc. stored in the memory unit 106 are storage means such as memory devices such as RAM and ROM, fixed disk devices such as hard disks, flexible disks, and optical disks, and store various programs, tables, databases, and web page files etc. used for various processes and providing websites.

[0101] The evaluation device 100 may be configured as an information processing device such as a known personal computer or a workstation, or may be configured as the information processing device to which any peripheral device is connected. The evaluation device 100 may be realized by installing software (including a program or data) that causes the information processing device to realize the evaluation method of the present invention.

[0102] Furthermore, the specific form of distribution and integration of the devices is not limited to that shown in the drawings, and all or part of them can be functionally or physically distributed and integrated in any unit according to various additions or functional loads. In other words, the above-mentioned embodiments can be implemented in any combination, or the embodiments can be implemented selectively. EXAMPLES

[0103] Amino acid concentrations in blood samples taken from 72 lung cancer patients who underwent surgical treatment before and after surgery were measured using the measurement method (A) described in the above embodiment. Of the 72 cases, 14 were cases of recurrence.

[0104] The concentration data of 21 amino acids, Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Trp, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, and Gly, in non-recurrence cases are shown in Figure 14. In Figure 14, the horizontal axis represents the preoperative value (pre) and postoperative value (post) of each amino acid concentration, and the vertical axis represents the average value of each amino acid concentration. The results of Student's t-test showed that Glu, Ser, a-ABA, Val, Met, Lys, Ile, Leu, and Trp were significantly decreased after surgery compared to before surgery (*: p<0.05, **: p<0.01, ***: p<0.001).

[0105] Meanwhile, the concentration data of the 21 amino acids in the recurrent cases are shown in Figure 15. In Figure 15, the horizontal axis represents the preoperative value (pre) and postoperative value (post) of each amino acid concentration, and the vertical axis represents the average value of each amino acid concentration. As a result of Student's t-test, no amino acids were significantly changed after surgery compared to before surgery.

[0106] FIG. 16 shows a radar chart indicating "the distribution of each amino acid after surgery when each amino acid before surgery is set to 100%" for recurrence-free cases. FIG. 17 shows a radar chart indicating "the distribution of each amino acid after surgery when each amino acid before surgery is set to 100%" for recurrence cases. The changes in the amino acid profile in recurrence-free cases differed from those in recurrence cases. It was therefore revealed that there is a specific change in the plasma amino acid profile when recurrence is likely to occur.

[0107] From the above, it was found that Glu, Ser, a-ABA, Val, Met, Lys, Ile, Leu and Trp, which showed significant differences only before and after surgery in non-recurrence cases, have the ability to discriminate the possibility of cancer recurrence. EXAMPLES

[0108] Using the same plasma amino acid concentration data as in Example 1, a logistic regression analysis was performed with the presence or absence of recurrence (binary variable) as the objective variable (FIG. 18). The logistic regression analysis was performed for each of the cases where the preoperative value (pre) was used as the explanatory variable, the postoperative value (post) was used as the explanatory variable, and the value obtained by subtracting the preoperative value from the postoperative value (post-pre) was used as the explanatory variable.

[0109] When pre was used as an explanatory variable, His, Met, and Trp changed significantly, when post was used as an explanatory variable, His, a-ABA, and Orn changed significantly, and when post-pre was used as an explanatory variable, Pro and Trp changed significantly (p<0.05, Wald's Test). This demonstrated that the amino acid variables His, Met, Trp, a-ABA, Orn, and Pro have the ability to discriminate the possibility of cancer recurrence. EXAMPLES

[0110] Using the same preoperative values ​​(pre) of plasma amino acid concentration data as in Example 1, a multivariate discriminant (multivariate function) for discriminating the possibility of cancer recurrence, which includes plasma amino acid concentrations as variables and is effective for evaluating the possibility of cancer recurrence, was determined.

[0111] Using the method described in WO 2004 / 052191, a combination of variables to be included in the logistic regression equation was searched for, and a logistic regression equation that maximizes the discrimination performance of the possibility of cancer recurrence was eagerly searched for.

[0112] In the above search, the explanatory variable was the preoperative value (pre), and the objective variable was the presence or absence of recurrence (binary variable). Combinations of 2 to 4 variables obtained by exhaustive testing were evaluated using ROC_AUC, and combinations of 2 to 4 variables with ROC_AUC greater than 0.7 were extracted.

[0113] A list of combinations of two variables with ROC_AUC greater than 0.7 is shown in Figure 19. Specific amino acid combinations are (Arg,Trp), (Orn,Trp), (Cit,Trp), (His,Cit), (His,Orn), (His,Arg), (Val,Orn), (Tyr,Trp), (Gln,His), (Met,Orn), (Ala,Orn), (Asn,His), (Cit,Met), (Orn,Lys), (His,Thr), (Glu,Trp), (His,Trp), (Thr,Trp), (Orn,Phe), (Orn,Leu), (Phe,Tr p), (Gln,Met), (Orn,Ile), (Cit,Val), (Glu,His), (Asn,Trp), (Ser,Orn), (Val,Ile), (Ile,Trp), (Leu,Trp), (Ala,Trp), (a_ABA,Trp), (Asn,Orn), (Val,Trp), (Lys,Trp), (Pro,Trp), (Ser,Trp), (His,Ile), (a_ABA,Orn), (Cit,Phe), (Arg,Met) and (Tyr,Orn).

[0114] In addition, there were 515 combinations of three variables with ROC_AUC greater than 0.7. Figure 20 shows a list of combinations of three variables with ROC_AUC greater than the maximum ROC_AUC for combinations of two variables. Specific amino acid combinations are: (Arg,Orn,Trp), (Glu,Met,Orn), (Cit,Orn,Trp), (Orn,Lys,Trp), (His,Cit,Orn), (Cit,Arg,Trp), (Glu,Orn,Trp), (Arg,Lys,Trp), (His,Arg,Trp), (Cit,Val,Orn), (Orn,Leu,Trp), (His,Cit,Trp), (Arg,Tyr,Trp), (Gln,His,Cit), (Val,Orn,Trp), (Ser,Cit,Trp), (Met,Orn,Trp), (Arg,Met,Trp), (Arg,Met,Orn), (Glu,Arg,Trp), p), (Asn,Arg,Trp), (Arg,Pro,Trp), (Pro,Orn,Trp), (His,Arg,Orn), (a_ABA,Orn,Trp), (Ser,Arg,Trp), (Ala,Orn,Trp), (Gln,His,Arg), (Thr,Arg,Trp), (Arg,Leu,Trp), (Orn,Phe,Trp), (Ser,Orn,Trp), (Asn,Orn,Trp), (Gly,Arg,Trp), (Gly,Orn,Trp), (Thr,Orn,Trp), (Cit,Lys,Trp), (Arg,a_ABA,Trp), (Tyr,Orn,Trp) and (Orn,Ile,Trp).

[0115] Furthermore, there were 3,369 combinations of four variables with ROC_AUC greater than 0.7. Figure 21 shows a list of combinations of four variables with ROC_AUC greater than the maximum ROC_AUC for combinations of three variables. The specific amino acid combinations were (Arg,Orn,Lys,Trp), (Arg,Met,Orn,Trp), (Ser,Arg,Orn,Trp), (Arg,a_ABA,Orn,Trp), (His,Arg,Orn,Trp), (Arg,Val,Orn,Trp), (Arg,Orn,Ile,Trp), (Glu,Arg,Met,Orn), (Gly,Arg,Orn,Trp), (Cit,Orn,Leu,Trp), (Thr,Arg,Orn,Trp), (Arg,Orn,Phe,Trp), (Arg,Tyr,Orn,Trp) and (Ala,Arg,Orn,Trp).

[0116] From the above, it was revealed that the amino acid combinations shown in Figures 19-21 have the ability to discriminate the possibility of cancer recurrence as amino acid variables. EXAMPLES

[0117] Based on the same plasma amino acid concentration data as in Example 1, a value obtained by subtracting a preoperative value from a postoperative value (post-pre) was calculated to obtain change amount data regarding the difference. Using the obtained change amount data, a multivariate discriminant (multivariate function) for discriminating the possibility of cancer recurrence containing plasma amino acid concentrations as variables, which is effective for evaluating the possibility of cancer recurrence, was obtained.

[0118] Using the method described in WO 2004 / 052191, a combination of variables to be included in the logistic regression equation was searched for, and a logistic regression equation that maximizes the discrimination performance of the possibility of cancer recurrence was eagerly searched for.

[0119] In the above search, the explanatory variable was the postoperative value minus the preoperative value (post-pre), and the objective variable was the presence or absence of recurrence (binary variable). Combinations of 2 to 4 variables obtained by exhaustive variable analysis were evaluated using ROC_AUC, and combinations of 2 to 4 variables with ROC_AUC greater than 0.7 were extracted.

[0120] A list of combinations of two variables with ROC_AUC greater than 0.7 is shown in Figure 22. Specific amino acid combinations were (Ala,Trp), (Pro,Trp), (Cit,Trp), (Glu,Leu), (Arg,Trp), (Phe,Trp), (Glu,Trp), (Cit,Val), (Glu,Pro), (Orn,Trp), (Glu,Val), (Lys,Trp), (Glu,Ala), (Tyr,Trp), (His,Trp), (Asn,Trp), and (Leu,Trp).

[0121] In addition, there were 241 combinations of three variables with ROC_AUCs greater than 0.7. Figure 23 shows a list of combinations of three variables with ROC_AUCs greater than the maximum value of ROC_AUCs for combinations of two variables. The specific amino acid combinations are (Pro, Tyr, Trp), (Glu, Pro, Leu), (Tyr, Phe, Trp), (Arg, Pro, Lys), (Arg, Pro, Trp), (Ala, Ile, Leu), (Ala, Arg, Trp), (Arg, Lys, Trp), (Pro, Tyr, Phe), (Glu, Ile, Leu), (Thr, Pro, Lys ... u,Pro,Lys), (Thr,Pro,Tyr), (Ala,Tyr,Trp), (Cit,a_ABA,Leu), (Cit,Phe,Trp), (Arg,Pro,Phe), (Gl u,Ala,Leu), (Glu,Cit,Leu), (Glu,Arg,Leu), (Arg,Pro,Leu), (His,Ala,Trp) and (Arg,Phe,Trp).

[0122] Furthermore, there were 2012 combinations of four variables with ROC_AUC greater than 0.7. A list of combinations of four variables with ROC_AUC greater than the maximum ROC_AUC for combinations of three variables is shown in Figure 24. The specific amino acid combinations are (Glu, Ala, Ile, Leu), (Thr, Pro, Tyr, Met), (Pro, Tyr, Phe, Trp), (Thr, Pro, Tyr, Trp), (Thr, Pro, Tyr, Lys), (Arg, Pro, Tyr, Phe), (Arg, Pro, Tyr, Trp), (Arg, Pro, Ile, Leu), (Arg, Pro, Lys, Trp), (Glu, Thr, Pro, Lys), (Arg, Pro, Tyr, Leu), (Thr, Pro, Ty r,Phe), (Cit,Tyr,Phe,Trp), (Ala,Tyr,Phe,Trp), (Arg,Pro,Lys,Ile), (Pro,Tyr,Leu,Trp), (Glu,Tyr,Phe,Trp), (Thr,Arg,Pro,Ly s), (Gly,Pro,Tyr,Trp), (Gln,Pro,Tyr,Trp), (His,Pro,Tyr,Trp), (Thr,Pro,Tyr,Leu), (Cit,Pro,a_ABA,Leu), (Glu,Pro,Ile,Leu), (Pro,a_ABA,Tyr,Phe), (a_ABA,Tyr,Leu,Trp), (Ser,Pro,Tyr,Trp), (Asn,Thr,Pro,Tyr), (His,Tyr,Val,Trp), (Glu,Thr,Ala,Lys), (Gly,Thr,Pro,Tyr), (Glu,a_ABA,Ile,Leu), (a_ABA,Tyr,Phe,Trp), (Glu,Thr,Ala,Leu), (Ala,Arg,Phe,Trp), (Glu,Pro,Tyr,Phe), ( Ala,a_ABA,Ile,Leu), (Pro,a_ABA,Tyr,Trp), (Pro,Tyr,Val,Trp), (Glu,Pro,Val,Leu), (Glu,Pro,Orn,Leu), (Ala,Arg,Tyr,Trp), (A la,Ile,Leu,Trp), (Cit,a_ABA,Ile,Leu), (Glu,Pro,Tyr,Trp), (Cit,Pro,Tyr,Phe), (Arg,Pro,Tyr,Lys), (Pro,Tyr,Ile,Trp), (Arg,Pro,Lys,Phe), (Ala,Arg,Lys,Trp), (Glu,Cit,Phe,Trp), (Ala,Arg,a_ABA,Leu), (Pro,a_ABA,Ile,Leu), (Pro,Tyr,Ile ,Leu), (Thr,Cit,Pro,Lys), (Glu,Cit,Pro,Leu), (Arg,Tyr,Phe,Trp), (Glu,His,Pro,Leu) and (Arg,Pro,Leu,Trp). ,

[0123] From the above, it was revealed that the amino acid combinations shown in Figures 22-24 have the ability to discriminate the possibility of cancer recurrence as amino acid variables. [Industrial Applicability]

[0124] INDUSTRIAL APPLICABILITY As described above, the present invention can be widely implemented in many industrial fields, particularly in the fields of pharmaceuticals, food, medicine, etc., and is particularly useful in the field of bioinformatics for evaluating cancer recurrence. [Explanation of symbols]

[0125] 100 Evaluation Device 102 Control section 102a Receiving section 102b Specified part 102c Expression Creation Section 102d Evaluation Section 102d1 Calculation part 102d2 Converter 102d3 Generation part 102d4 Classification section 102e Result output section 102f Transmitter 104 Communication interface section 106 Storage section 106a Concentration data file 106b Index status information file 106c Specified index status information file 106d type related information database 106d1 Formula File 106e Evaluation result file 108 Input / Output Interface Section 112 Input Devices 114 Output Device 200 Client device (terminal device (information communication terminal device)) 300 Network 400 Database device

Claims

1. The method includes an acquisition step of acquiring information for evaluating the possibility of recurrence of lung cancer for a subject in whom lung cancer has been found, using a value of a logistic regression equation calculated using a concentration value of Ser in the blood of the subject in whom lung cancer has been found and a variable into which the concentration value is substituted, the value being determined on the assumption of discrimination ability using ROC_AUC; An acquisition method characterized by the above.

2. the value of the formula is calculated using the logistic regression formula further including a concentration value of Ser in the blood, a concentration value of at least one amino acid selected from Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, a-ABA, and Gly in the blood, and a variable into which the concentration value of the at least one amino acid is substituted; The acquisition method according to claim 1 ,

3. the acquiring step is executed by a control unit of an information processing device including a control unit; The acquisition method according to claim 1 or 2, characterized in that:

4. The method includes a calculation step of calculating the value of a logistic regression equation for evaluating the possibility of recurrence of lung cancer, the equation including a concentration value of Ser in the blood of a subject in whom lung cancer has been found and a variable into which the concentration value is substituted, the equation being obtained on the premise of discrimination ability by ROC_AUC; A calculation method characterized by:

5. the calculation step is executed by a control unit of an information processing device including a control unit; The calculation method according to claim 4, characterized in that

6. An evaluation device including a control unit, The control unit is An evaluation means for evaluating the possibility of recurrence of lung cancer in a subject in whom lung cancer has been found in the past, using a value of a logistic regression equation including a concentration value of Ser in the blood of the subject in whom lung cancer has been found in the past and a variable into which the concentration value is substituted, the value being calculated based on the discrimination ability by ROC_AUC. Having the following features: An evaluation device comprising:

7. A terminal device that provides the value of the formula is communicatively connected via a network; The control unit is a data receiving means for receiving the value of the formula transmitted from the terminal device; a result transmission means for transmitting the evaluation result obtained by the evaluation means to the terminal device; Further equipped with said evaluation means using the value of said formula received by said data receiving means; The evaluation device according to claim 6 .

8. A calculation device including a control unit, The control unit is A calculation means for calculating a value of a logistic regression equation for evaluating the possibility of recurrence of lung cancer, the equation including a concentration value of Ser in the blood of a subject who has been previously diagnosed with lung cancer and a variable into which the concentration value is substituted, the equation being obtained on the premise of discrimination ability by ROC_AUC. Having the following features: A calculation device comprising:

9. An evaluation program to be executed in an information processing device having a control unit, To be executed in the control unit, An evaluation step of evaluating the possibility of recurrence of lung cancer in the subject using a value of a logistic regression equation including a concentration value of Ser in the blood of the subject who has been found to have lung cancer and a variable into which the concentration value is substituted, the equation being calculated on the assumption of discrimination ability by ROC_AUC. containing, An evaluation program that features:

10. A calculation program to be executed in an information processing device having a control unit, To be executed in the control unit, A calculation step of calculating the value of a logistic regression equation for evaluating the possibility of recurrence of lung cancer, the equation including a concentration value of Ser in the blood of a subject who has been found to have lung cancer and a variable into which the concentration value is substituted, the equation being obtained on the premise of discrimination ability by ROC_AUC. containing, A calculation program comprising:

11. An evaluation system configured by connecting an evaluation device having a control unit and a terminal device having a control unit via a network so as to be able to communicate with each other, The control unit of the terminal device a data transmitting means for transmitting to the evaluation device a concentration value of Ser in the blood of an evaluation subject who has been found to have lung cancer and a value of the said equation calculated using a logistic regression equation including variables into which the concentration value is substituted, the said equation being obtained on the premise of discrimination ability by ROC_AUC; a result receiving means for receiving an evaluation result regarding the possibility of lung cancer recurrence transmitted from the evaluation device; Equipped with The control unit of the evaluation device a data receiving means for receiving the value of the formula transmitted from the terminal device; an evaluation means for evaluating a possibility of recurrence of lung cancer in the subject by using the value of the formula received by the data receiving means; a result transmission means for transmitting the evaluation result obtained by the evaluation means to the terminal device; Having the following features: A rating system characterized by:

Citation Information

Patent Citations

  • Pancreas cancer risk disease evaluation method, pancreas cancer risk disease evaluation device, pancreas cancer risk disease evaluation method, pancreas cancer risk disease evaluation program, pancreas cancer risk disease evaluation system and information communication terminal device

    JP2014106114A

  • Organism condition information processor, organism condition information processing method, organism condition information managing system, program, and recording medium

    WO2004052191A1

  • Biocondition evaluating device, biocondition evaluating method, biocondition evaluating system, biocondition evaluating program, evaluation function generating device, evaluation function generating method, evaluation function generating program, and recording medium

    WO2006098192A1

  • Method for evaluation of lung cancer, lung cancer evaluation apparatus, lung cancer evaluation method, lung cancer evaluation system, lung cancer evaluation program, and recording medium

    WO2008016111A1

  • Method for evaluation of breast cancer, breast cancer evaluation apparatus, breast cancer evaluation method, breast cancer evaluation system, breast cancer evaluation program, and recording medium

    WO2008075662A1